Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:COYA NASDAQ:CRBP NYSEMKT:IGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$2.40+0.8%$1.90$0.80▼$3.42$98.59M-0.88171,843 shs41,063 shsCOYACoya Therapeutics$6.20+1.1%$5.95$4.65▼$10.24$103.73M0.2674,116 shs38,667 shsCRBPCorbus Pharmaceuticals$9.59+7.0%$8.54$4.64▼$61.89$117.53M3.2189,076 shs154,112 shsIGCIGC Pharma$0.36+10.1%$0.34$0.25▼$0.48$30.83M1.48913,992 shs214,616 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals+0.42%-9.85%+43.37%+142.86%+20.20%COYACoya Therapeutics-0.33%-4.67%0.00%+7.73%+16.10%CRBPCorbus Pharmaceuticals+3.34%+0.67%+8.34%+27.27%-82.90%IGCIGC Pharma-2.25%-1.14%-8.68%+15.67%-14.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANEBAnebulo Pharmaceuticals2.1989 of 5 stars3.33.00.00.02.81.70.0COYACoya Therapeutics2.0359 of 5 stars3.53.00.00.02.30.80.0CRBPCorbus Pharmaceuticals4.3078 of 5 stars3.63.00.04.72.82.50.0IGCIGC Pharma1.7511 of 5 stars3.50.00.00.01.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 2.50Moderate Buy$5.50129.17% UpsideCOYACoya Therapeutics 3.00Buy$16.50166.13% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$49.00410.95% UpsideIGCIGC Pharma 3.00Buy$3.88979.39% UpsideCurrent Analyst Ratings BreakdownLatest IGC, CRBP, ANEB, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/13/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.008/6/2025CRBPCorbus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $53.007/30/2025CRBPCorbus PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$28.007/24/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.007/23/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/12/2025CRBPCorbus PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/9/2025COYACoya TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/1/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/9/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/15/2025ANEBAnebulo PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.00(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.15 per shareN/ACOYACoya Therapeutics$3.55M29.22N/AN/A$2.37 per share2.62CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$9.06 per shareN/AIGCIGC Pharma$1.27M25.65N/AN/A$0.08 per share4.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.20M-$0.26N/A∞N/AN/A-90.11%-84.53%9/24/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%N/ACRBPCorbus Pharmaceuticals-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%N/AIGCIGC Pharma-$13M-$0.08N/AN/AN/A-714.16%-122.44%-88.40%N/ALatest IGC, CRBP, ANEB, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025COYACoya Therapeutics-$0.22-$0.36-$0.14-$0.36$0.78 million$0.16 million8/5/2025Q2 2025CRBPCorbus Pharmaceuticals-$1.55-$1.44+$0.11-$1.44N/AN/A5/13/2025Q3 2025ANEBAnebulo Pharmaceuticals-$0.05-$0.04+$0.01-$0.04N/AN/A5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A25.2925.29COYACoya TherapeuticsN/A8.848.84CRBPCorbus PharmaceuticalsN/A9.219.21IGCIGC Pharma0.021.150.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%COYACoya Therapeutics39.75%CRBPCorbus Pharmaceuticals64.64%IGCIGC Pharma3.87%Insider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%COYACoya Therapeutics12.00%CRBPCorbus Pharmaceuticals4.00%IGCIGC Pharma31.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals441.08 million7.97 millionNot OptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableCRBPCorbus Pharmaceuticals4012.26 million11.77 millionOptionableIGCIGC Pharma6190.81 million54.60 millionN/AIGC, CRBP, ANEB, and COYA HeadlinesRecent News About These CompaniesIGC Pharma, Inc.: IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1August 13 at 7:47 AM | finanznachrichten.deIGC Pharma highlights preclinical data on IGC-M3August 12 at 4:43 PM | msn.comIGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1August 12 at 9:00 AM | accessnewswire.comAIGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease ProgressionAugust 5, 2025 | accessnewswire.comAIGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025July 23, 2025 | accessnewswire.comAIGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience AwardsJuly 21, 2025 | accessnewswire.comAIGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict ...July 12, 2025 | morningstar.comMIGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early DetectionJuly 11, 2025 | finanznachrichten.deIGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early DetectionJuly 10, 2025 | accessnewswire.comAEarnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.comJuly 2, 2025 | investing.comIGC Pharma earnings matched, revenue fell short of estimatesJuly 2, 2025 | investing.comEarnings call transcript: IGC Pharma Q2 2025 sees strategic growth in Alzheimer’s research - Investing.com UKJuly 2, 2025 | uk.investing.comIGC Pharma, Inc.: IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's InnovationJune 30, 2025 | finanznachrichten.deIGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's InnovationJune 30, 2025 | accessnewswire.comAIGC Pharma, Inc.: IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - FinanzNachrichten.deJune 28, 2025 | finanznachrichten.deIGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - MorningstarJune 28, 2025 | morningstar.comMIGC Pharma Inc Trailing Returns - MorningstarJune 27, 2025 | morningstar.comMIGC Pharma Inc. Annual Cash Flow Statement - MarketWatchJune 27, 2025 | marketwatch.comInsights Ahead: IGC Pharma's Quarterly EarningsJune 27, 2025 | benzinga.comIGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue EstimatesJune 27, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGC, CRBP, ANEB, and COYA Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$2.40 +0.02 (+0.84%) Closing price 04:00 PM EasternExtended Trading$2.38 -0.02 (-0.63%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Coya Therapeutics NASDAQ:COYA$6.20 +0.07 (+1.14%) Closing price 04:00 PM EasternExtended Trading$6.19 -0.01 (-0.16%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Corbus Pharmaceuticals NASDAQ:CRBP$9.59 +0.63 (+7.03%) Closing price 04:00 PM EasternExtended Trading$9.54 -0.04 (-0.47%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.IGC Pharma NYSEMKT:IGC$0.36 +0.03 (+10.09%) Closing price 03:58 PM EasternExtended Trading$0.36 +0.00 (+0.28%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Why BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Catalysts Align: Archer Beats Estimates, Delivers Aircraft to UAE Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.